Clinical trial
A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer Subjects Who Have Not Responded to Standard Treatment or Relapsed After Standard Treatment
NCT01357395 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer Subjects Who Have Not Responded to Standard Treatment or Relapsed After Standard Treatment
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2011
- Completion date
- May 28, 2012
- Enrollment
- 23 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.